Oculis (OCS) investor relations material

Pipeline overview and clinical progress

• Two advanced programs in phase III: Licaminlimab for TNFR1 dry eye and Privosegtor for acute optic neuritis.

• Licaminlimab uses a precision medicine approach, genotyping patients for targeted treatment, with phase III readout expected late 2026 or early 2027.

• Privosegtor, a neuroprotective agent, has shown strong phase II results and is in phase III with FDA breakthrough and EMA prime designations.

• Both programs are in registration trials, with Privosegtor also being explored for MS relapses and NAION.

• The company is well-financed through the second half of 2029, supporting ongoing and planned trials.

Licaminlimab: Dry eye disease program

• Licaminlimab targets severe TNFR1-positive dry eye patients, using a qPCR saliva test for genotype selection.

• Phase II data showed a sevenfold improvement in symptoms for TNFR1 patients; phase III focuses on symptom improvement in this group.

• The drug is a topical antibody fragment administered as an eye drop three times daily.

• Market potential includes 1.8 million TNFR1-positive patients in the U.S., with pricing expected to exceed current branded therapies.

• Additional indications include uveitis, with plans for further development as a steroid-sparing agent.

Privosegtor: Acute optic neuritis and neuroprotection

• Privosegtor was acquired to avoid royalties and milestones, and has advanced from phase I to phase III in three years.

• Demonstrated significant functional and structural benefits in phase II, including improved LCVA and reduced retinal atrophy.

• No current therapies alter prognosis in acute optic neuritis; Privosegtor addresses a major unmet need.

• PIONEER-1 phase III trial is activating sites globally, aiming for 50% site activation by December to align with disease seasonality.

• Commercial opportunity estimated at $3.5 billion in the U.S. alone, with pricing in line with orphan indications.